Bromley Elizabeth
Semel Institute Health Services Research Center, University of California, Los Angeles, 10920 Wilshire Boulevard, Suite 300, Los Angeles, CA 90024-6505, USA.
Schizophr Bull. 2007 May;33(3):648-51. doi: 10.1093/schbul/sbm024. Epub 2007 Apr 9.
Several compounds to improve cognition in schizophrenia are being studied in clinical trials, but little is known about how clinicians conceptualize the cognitive deficits of schizophrenia. In a pilot study, the author asked 40 psychiatrists 3 brief questions about the clinical presentation of cognitive deficits. Descriptions of cognitive deficits show high variability. Informants describe phenomenology like follow-through, attention, and emptiness as indicative of cognitive impairment. Informants' concepts of cognitive deficits overlap substantially with positive, negative, and thought disorder symptoms. Clinicians' concepts are complex and contextualized, in contrast to the discrete skills measured by neuropsychological tests. Results suggest that appropriate prescribing of cognition-enhancing medications may be challenging.
几种用于改善精神分裂症认知功能的化合物正在临床试验中进行研究,但对于临床医生如何看待精神分裂症的认知缺陷却知之甚少。在一项试点研究中,作者向40位精神科医生询问了3个关于认知缺陷临床表现的简短问题。对认知缺陷的描述显示出高度的变异性。受访者将如贯彻始终、注意力和空虚感等现象学表现描述为认知障碍的指征。受访者对认知缺陷的概念与阳性、阴性和思维障碍症状有很大重叠。与神经心理学测试所测量的离散技能不同,临床医生的概念是复杂且情境化的。结果表明,合理开具改善认知的药物可能具有挑战性。